HIGHLIGHTS
- who: Luca De Nicola from the (UNIVERSITY) have published the Article: Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?, in the Journal: (JOURNAL)
- what: The main focus of CKD treatment has now become preserving renal function rather than replacing it. Increasing awareness of CKD is one of the main goals of the nephrology community . The study showed that among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events (HR 0.88; 95.8% CI 0.75-1.03; P=0 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.